ESMO 2026 | TroFuse-005: sacituzumab tirumotecan in pretreated advanced endometrial cancer
Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, comments on results from the Phase III TroFuse-005/ENGOT-en23/GOG-3095 study (NCT06132958), which evaluated sacituzumab tirumotecan, a TROP2-directed antibody-drug conjugate (ADC), versus treatment of physician’s choice in patients with advanced or recurrent endometrial cancer previously treated with platinum and immunotherapy. Sacituzumab tirumotecan significantly improved progression-free survival, overall survival and response rates, with manageable safety and maintained quality of life. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
